SCHEMBL1770933

SCHEMBL1770933

C[C](Cl)CO

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29151153 0.70
SCHEMBL6722324 0.70
SCHEMBL3418925 0.70
SCHEMBL775638 0.70
Alcohol SCHEMBL28092781 0.67
SCHEMBL40167 0.67
SCHEMBL6719506 0.67
SCHEMBL337523 0.65
SCHEMBL9426 0.65
Methyl Alcohol SCHEMBL4870551 0.65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220185778-A1 PROLYL HYDROXYLASE INHIBITORS AERPIO THERAPEUTICS INC (US) 2022-06-16 US disclosed
EP-3698794-A1 COMPOSITIONS AND METHODS FOR TREATING COLITIS Aerpio Therapeutics, Inc. (US) 2020-08-26 EP disclosed
US-10562854-B2 Prolyl hydroxylase inhibitors AERPIO THERAPEUTICS, INC. (US) 2020-02-18 US disclosed
EP-3603644-A1 PROLYL HYDROXYLASE INHIBITORS Aerpio Therapeutics, Inc. (US) 2020-02-05 EP disclosed
EP-2952192-B1 Prolyl hydroxylase inhibitors AERPIO THERAPEUTICS INC (US) 2019-05-15 EP disclosed
US-20190055198-A1 PROLYL HYDROXYLASE INHIBITORS AERPIO THERAPEUTICS LLC 2019-02-21 US disclosed
US-10040922-B2 Oxygen scavengers, compositions comprising the scavengers, and articles made from the compositions PLASTIPAK PACKAGING, INC. (US) 2018-08-07 US disclosed
US-20170298019-A1 PROLYL HYDROXYLASE INHIBITORS AERPIO THERAPEUTICS LLC 2017-10-19 US disclosed
EP-2853265-B1 Methods for increasing the stabilization of hypoxia inducible factor-1 alpha AERPIO THERAPEUTICS INC (US) 2017-07-26 EP disclosed
US-9540326-B2 Prolyl hydroxylase inhibitors AERPIO THERAPEUTICS, INC. (US) 2017-01-10 US disclosed
EP-2496236-A1 PROLYL HYDROXYLASE INHIBITORS Aerpio Therapeutics Inc. (US) 2012-09-12 EP disclosed
EP-2496084-A1 COMPOSITIONS AND METHODS FOR TREATING COLITIS Aerpio Therapeutics Inc. (US) 2012-09-12 EP disclosed
US-20110172335-A1 OXYGEN SCAVENGERS, COMPOSITIONS COMPRISING THE SCAVENGERS, AND ARTICLES MADE FROM THE COMPOSITIONS WELLS FARGO BANK, N.A., AS ADMINISTRATIVE AGENT 2011-07-14 US disclosed
WO-2011060304-A2 OXYGEN SCAVENGERS, COMPOSITIONS COMPRISING THE SCAVENGERS, AND ARTCLES MADE FROM THE COMPOSITIONS CONSTAR INTERNATIONAL, INC. (US) 2011-05-19 WO disclosed
WO-2011057121-A1 COMPOSITIONS AND METHODS FOR TREATING COLITIS AKEBIA THERAPEUTICS INC. (US) 2011-05-12 WO disclosed
US-20110110961-A1 PROLYL HYDROXYLASE INHIBITORS AERPIO THERAPEUTICS LLC 2011-05-12 US disclosed
US-20110111058-A1 METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA AERPIO THERAPEUTICS LLC 2011-05-12 US disclosed
US-20110112055-A1 COMPOSITIONS AND METHODS FOR TREATING COLITIS AERPIO THERAPEUTICS LLC 2011-05-12 US disclosed
WO-2011057112-A1 METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA AKEBIA THERAPEUTICS INC. (US) 2011-05-12 WO disclosed
WO-2011057115-A1 PROLYL HYDROXYLASE INHIBITORS AKEBIA THERAPEUTICS INC. (US) 2011-05-12 WO disclosed